Editorial

Brendan J. Moran and Alexios Tzivanakis

The concept of "Obstruction-Free Survival" as an outcome measure in advanced colorectal cancer management

https://doi.org/10.1515/pap-2018-0101

Despite improvements in diagnosis, imaging, surgical technique and chemotherapeutic agents, the majority of patients with synchronous, or metachronous, metastatic abdominal cancer ultimately die from the disease. In the context of advanced cancer, peritoneal malignancy is a particular problem, whether primary peritoneal malignancy (for example peritoneal mesothelioma) or peritoneal metastases from gastro-intestinal tract cancers. An added distressing, and life limiting, aspect of peritoneal malignancy is that bowel obstruction is common and often a terminal event. Malignant bowel obstruction is devastating for patients and distressing for relatives and healthcare workers, as it is often impossible to effectively palliate by medical treatments, endoscopic stenting or by surgical intervention. The combination of intestinal colic, with an inability to eat and drink, combined with the general need for a permanent nasogastric tube has major detrimental effects on the final period of a terminal illness.

Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy have recently been established as a treatment strategy for selected patients with peritoneal malignancy of appendiceal [1] colorectal [2, 3], mesothelioma [4] and other malignancies within the peritoneal cavity. Despite successful intervention in some patients, the majority still succumb to disease and furthermore many are never suitable for CRS due to extent of peritoneal carcinomatosis.

The commonest tumours treated by CRS and HIPEC are peritoneal malignancy from the appendix [5, 6] or colorectal cancer [2]. Colorectal cancer can present with synchronous peritoneal disease or as metachronous recurrence and in many cases recurrence may be peritoneal alone. In many patients peritoneal disease is extensive and best described as carcinomatosis and not amenable to complete removal by CRS. For this reason the concept of resectable colorectal peritoneal metastases [3] is a useful terminology in defining patients who are amenable to complete tumour removal and potential for cure in 20–30% of cases, though the

remainder usually succumb from tumour recurrence. While optimal results are achieved with complete tumour removal (and ideally CCO surgery), it has also been noted that patients with CC1, or even CC2, may benefit if surgery is combined with HIPEC [7].

An anecdotal personal observation, over a number of years' experience with substantial numbers of patients, by the first author (BJM), has been the hypothesis that, despite high recurrence rates, after optimal CRS and HIPEC, bowel obstruction may be reduced where HIPEC has been administered. There are some potential mechanisms for this effect in that the most commonly used agent (Mitomycin C) has anti-adhesion properties and is used in ophthalmic surgery after tear-duct and other procedures to reduce scarring [8, 9]. There has also been some animal experimental work showing a reduction in intraperitoneal adhesions with Mitomycin C [10, 11].

In addition a cytotoxic effect on peritoneal tumour on the small bowel might have an additive effect. This hypothesis stimulates the concept of "obstruction free survival" as a new measure of a beneficial effect of intraperitoneal chemotherapy which may have profound effects on quality of life in patients with advanced cancer involving the peritoneum.

Indeed, in retrospect, the seminal paper by Sugarbaker et al. in 1985 [12], did suggest possible reduction in obstruction free survival. In this randomized trail 4/30 who had systemic chemotherapy required surgery for small bowel obstruction compared with 1/36 patients who had intra-peritoneal chemotherapy.

For many years we have been frustrated by the limitations of CRS and HIPEC due to poor outcomes in patients with high PCI scores, the high morbidity, occasional mortality and high cost with poor long-term outcomes when survival is the primary end point. For patients with diffuse carcinomatosis, up until now, there have been few alternative options. However, a recent major development in advanced peritoneal malignancy has been pressurized intra-peritoneal chemotherapy (PIPAC), which has benefits in disease control where complete tumour removal by CRS

is not feasible [13, 14]. These advanced cases need new endpoints as long-term survival for most patients is unlikely.

Obstruction-free survival may be a true measurable benefit of PIPAC and HIPEC and should be included in all evaluations of these therapies in peritoneal malignancy. We may have over-looked real benefits to patients in the pursuit of the Holy Grail where cure is unlikely or impossible.

Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Research funding: None declared.

Employment or leadership: None declared.

Honorarium: None declared.

References

- 1. Moran B, Baratti D, Yan TD, Kusamura S, Deraco M. Consensus statement on the loco-regional treatment of appendiceal mucinous neoplasms with peritoneal dissemination (pseudomyxoma peritonei). J Surg Oncol 2008;15:9.
- 2. https://www.nice.org.uk/guidance/ipg331.
- 3. Moran BJ, Cecil TD. Treatment of surgically resectable colorectal peritoneal metastases. Br J Surg 2014;101:5-7.
- 4. García-Fadrique A, Mehta A, Mohamed F, Dayal S, Cecil T, Moran BJ. Clinical presentation, diagnosis, classification and management of peritoneal mesothelioma: a review. J Gastrointest Oncol 2017;8:915.
- 5. Chua TC, Martin S, Saxena A, Liauw W, Yan TD, Zhao J, et al. Evaluation of the cost-effectiveness of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (peritonectomy) at the St George Hospital peritoneal surface malignancy program. Ann Surg 2010;251:323-9.
- 6. Ansari N, Chandrakumaran K, Dayal S, Mohamed F, Cecil TD, Moran BJ. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1000 patients with perforated appendiceal epithelial tumours. Eur J Surg Oncol 2016;42:1035-41.

- 7. Elias D, Lefevre JH, Chevalier J, Brouguet A, Marchal F, Classe JM, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol 2008;27:681-5.
- 8. Feng YF, Yu JG, Shi JL, Huang JH, Sun YL, Zhao YE. A metaanalysis of primary external dacryocystorhinostomy with and without mitomycin C. Ophthalmic Epidemiol 2012;19: 364-70.
- 9. Cabourne E, Clarke JC, Schlottmann PG, Evans JR. Mitomycin C vs 5-Fluorouracil for wound healing in glaucoma surgery. The Cochrane Library. 2015:1.
- 10. Urkan M, Özerhan İH, Ünlü A, Can MF, Öztürk E, Günal A, et al. Prevention of intraabdominal adhesions: an experimental study using mitomycin-C and 4% icodextrin. Balkan Medical J 2017;34:5.
- 11. Ozerhan IH, Urkan M, Meral UM, Unlu A, Ersöz N, Demirag F, et al. Comparison of the effects of Mitomycin-C and sodium hyaluronate/carboxymethylcellulose [NH/CMC] (Seprafilm) on abdominal adhesions. Springer Plus 2016;5:846.
- 12. Sugarbaker PH, Gianola FJ, Speyer JC, Wesley R, Barofsky I, Meyers CE. Prospective, randomized trial of intravenous versus intraperitoneal 5-fluorouracil in patients with advanced primary colon or rectal cancer. Surgery 1985;98:414-22.
- 13. Girshally R, Demtröder C, Albayrak N, Zieren J, Tempfer C, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) as a neoadjuvant therapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World I Surg Oncol 2016;14:253.
- Odendahl K, Solass W, Demtröder C, Giger-Pabst U, Zieren J, Tempfer C, et al. Quality of life of patients with end-stage peritoneal metastasis treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC). Eur J Surg Oncol 2015; 41:1379-85.

Brendan J. Moran, Peritoneal Malignancy Institute Basingstoke, Basingstoke, United Kingdom of Great Britain and Northern Ireland, E-mail: brendan.moran@hhft.nhs.uk

Alexios Tzivanakis, Peritoneal Malignancy Institute, Basingstoke and North Hampshire Hospital, Basingstoke, United Kingdom of Great Britain and Northern Ireland, E-mail: alexios.tzivanakis@hhft.nhs.uk